Search Results

GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association’s Fall Conference from a Phase II trial in Alzheimer’s disease of lead candidate GV1001

GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’.

GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer’s, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.

Samsung Pharm Co., Ltd. announced that the company presented the results of a phase III clinical trial of its pancreatic cancer immunotherapeutic drug candidate called ‘RIAVAX™ ' conducted in Korea at the 2021 American Society of Clinical Oncology Annual meeting.

The 12th Clinical Trials on Alzheimer’s Disease 2019 was held in San Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer’s disease clinical trials were shared, and it provided a glimpse into the possibility of treating Alzheimer’s disease.